Company intelligence / Profile preview

Thrombosis Research Institute

London, England, United Kingdomtri-london.ac.uk ↗

Ownership: Private
Development stage: Commercial

Overview

The institute has pioneered the use of heparin for thrombosis prevention and was instrumental in developing low molecular weight heparins. It continues to lead large-scale clinical studies on antithrombotic therapies and registries for cardiovascular outcomes. Its work has contributed significantly to global guidelines for the management of blood clots. No proprietary drugs or commercial products are developed by TRI itself.

Therapeutic areas: CardiovascularHematology
Modalities: Small moleculeBiologicDeviceNon-pharmacological therapy
Industry: Academic Hospital/University/Research

Partnerships

Academic Health Science PartnershipUCL PartnersInternational network of over 2,500 research centers across ~40 countries

Beyond the preview

Go deeper on Thrombosis Research Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thrombosis Research Institute.

Explore the full profile